Drug and Medication Analysis & Statistics in France, August 2014 (p3)

You might be interested in: drug, vaccine, smoking cessation, more »

61-90 of about 200 reports

Purchase Reports From Reputable Market Research Publishers

Ginger S.A. - Strategic SWOT Analysis Review

Ginger S.A. - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • August 2014
  • by Global Data

Summary Ginger S.A. (Ginger) is a civil engineering and construction service provider. It provides research and survey related services to civil engineering and other construction projects. The company ...

  • Industries : Drug and Medication
  • Countries : France
Lavipharm S.A. (LAVI) - Financial and Strategic SWOT Analysis Review

Lavipharm S.A. (LAVI) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • August 2014
  • by Global Data

Summary Lavipharm S.A (Lavipharm) is a an integrated company, which carries out developing, manufacturing, marketing and distribution of pharmaceutical, cosmetic, consumer health and over the counter (OTC) ...

  • Industries : Drug and Medication
  • Countries : Greece, France, United States, Cyprus
NRT Smoking Cessation Aids Market Analysis in France

NRT Smoking Cessation Aids Market Analysis in France

  • $ 898
  • Industry report
  • June 2014
  • by Euromonitor International

However this legislation, put into force some years ago, seems to have reached its limits in terms of impact, as... Euromonitor International's report offers a comprehensive guide to the size and shape ...

  • Industries : Drug and Medication, Tobacco
  • Countries : France
Analgesics Market Analysis in France

Analgesics Market Analysis in France

  • $ 898
  • Industry report
  • June 2014
  • by Euromonitor International

However, there remained a lack of investment within the aspirin category, which partly explains the modest performance of analgesics in 2010. Aspirin continued to be threatened by consumers’ preference ...

  • Industries : Drug and Medication
  • Countries : France
Cough, Cold and Allergy (Hay Fever) Remedies Market Analysis in France

Cough, Cold and Allergy (Hay Fever) Remedies Market Analysis in France

  • $ 898
  • Industry report
  • June 2014
  • by Euromonitor International

In general, consumers are used to self-medicating with products from this category and they did not change their habits in 2010. However, the category faced stronger competition from some homoeopathic ...

  • Industries : Drug and Medication
  • Countries : France
Mold Inhibitors Market, By Type (Propionates, Sorbates, Benzoates, and Natamycin), By Application (Food, Feed, Paint, Pharmaceuticals, and Cosmetics) - Global Trends & Forecast to 2019

Mold Inhibitors Market, By Type (Propionates, Sorbates, Benzoates, and Natamycin), By Application (Food, Feed, Paint, Pharmaceuticals, and Cosmetics) - Global Trends & Forecast to 2019

  • $ 4 650
  • Industry report
  • May 2014
  • by MarketsandMarkets

The mold inhibitors market is expected to grow at a CAGR of 2.9% from 2014 to 2019. The estimation is made on the basis of the increasing health awareness among consumers as mold causes allergies, asthma, ...

  • Industries : Drug and Medication
  • Countries : World, North America, Europe, China, Mexico, Canada, India, South Africa, Brazil, France, Germany, Japan, United States
MarketVIEW: Group B Streptococcus

MarketVIEW: Group B Streptococcus

  • $ 4 495
  • Industry report
  • May 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Group B beta streptococci (GBS) or Streptococcus agalactiae is an encapsulated Gram-positive coccus capable of producing a range of diseases in humans of all age ranges. In the neonate, the bacterium can ...

  • Industries : Drug and Medication
  • Countries : United States, World, Australia, Africa, Brazil, Mexico, Canada, United Kingdom, Spain, Italy, France, Germany, Europe, North America
PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : Italy, Spain, France, Germany, United Kingdom, Europe, World
DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022

DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022

Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022

CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022

Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022

Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : Germany, United States, World, Spain, Italy, France, Europe, United Kingdom
Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022

Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : World, Europe, United States, Spain, Italy, France, Germany, United Kingdom
Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022

Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : World, United States, Spain, Italy, France, Germany, Europe, United Kingdom
Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022

Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
MarketVIEW: Cytomegalovirus (CMV) vaccines

MarketVIEW: Cytomegalovirus (CMV) vaccines

  • $ 4 495
  • Industry report
  • April 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas ...

  • Industries : Drug and Medication
  • Countries : United States, Canada, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Antidepressants (Migraine) - Forecast and Market Analysis to 2023

Antidepressants (Migraine) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

Antidepressants (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Japan, United States, World
Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available ...

  • Industries : Drug and Medication
  • Countries : Australia, Germany, World, Canada, Spain, Italy, France, Japan, Oceania, New Zealand, Europe, United States, United Kingdom
Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Canada, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Canada, Spain, Italy, France, Germany, United States, United Kingdom, Europe
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

  • $ 10 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became ...

  • Industries : Drug and Medication
  • Countries : World, Australia, Canada, Spain, Italy, United Kingdom, France, Germany, Japan, United States, Europe
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Germany, Spain, Italy, France, World, Europe, United States, United Kingdom, Japan
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : World, United Kingdom, Canada, Spain, Italy, France, Germany, Japan
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
About 100 reports

Download Unlimited Documents from Trusted Public Sources

Drug And Medication Market in Europe

  • Paracetamol in Osteoarthritis of the Knee
  • September 2014
    9 pages
  • Drug And Medica...  

    Paracetamol  

  • France  

View report >

Drug Markets In France

November 2013

2 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Select Products Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.